Pulished Date October, 2018
ID: 898
Share on
Share on

North America Hormone Replacement Therapy Market By Hormone Type (Estrogen Replacement Therapy, Growth Hormone Replacement Therapy, Thyroid Replacement Therapy And Others) By Route Of Administration (Oral, Parenteral, Transdermal And Others) And By Region - Industry Analysis, Size, Share, Growth, Trends, And Forecasts (2018-2023)

Pulished: October, 2018
ID: 898
Pages: 133

Hormone replacement therapy (HRT) is employed in patients suffering from declining levels of hormones with the right administration of hormones into the body. These therapies are generally meted out to women undergoing menopause. Estrogen is among the most commonly administered hormones. However, progesterone and testosterone are also administered when needed. The North America Hormone Replacement Therapy Market is estimated at USD 6.77 billion in 2018 and is predicted to reach USD 9.55 billion by 2023, growing at a CAGR of 7.12%.

Growing awareness on post-menopausal hazards, reimbursement policies, novel formulations, rise in unmet medical needs which require the employment of hormone therapy, benefits like lower risk of fractures are the few factors propelling the growth of North America hormone replacement therapy market.

However, based on research studies, hormone replacement therapy can cause severe side effects, such as bleeding, breast tenderness or enlargement, bloating, mood changes, headaches, and nausea, risk of breast cancer, heart disease, and stroke. Along with this, high cost of therapy is limiting its reach to middle class people.  Further, women with high susceptibility to coronary diseases are advised to stay away from hormone replacement therapy thereby decreasing the size of target audience.

The North America hormone replacement therapy is segmented on the basis of hormone type into Estrogen Replacement Therapy, Growth Hormone Replacement Therapy, Thyroid replacement therapy and others. The estrogen replacement therapy is the major segment as its employed by majority women to treat menopause, and is followed by growth hormone replacement therapy. Further, on the basis of route of administration the market is classified as oral, transdermal, parenteral, and other routes. Most of the times, therapies are carried out through oral routes, followed by parenteral administrations.

Morover, on the basis of geography, the North America hormone replacement therapy market is analysed under USA and Canada countries. USA dominates the market in the region owing to the economic conditions, awareness among women and government reimbursement policies present.

Some of the key players operating in the North America hormone replacement industry are Novartis, Abbott Laboratories, Pfizer, Mylan Laboratories, F. Hoffmann-La Roche, Merck & Co., Amgen, Eli Lily, Bayer,Novo Nordisk, Wyeth, Hisamitsu Pharmaceutical Co. Inc.


                1.1 Market Definition                                                    

                1.2 Study Deliverables                                                  

                1.3 Base Currency, Base Year and Forecast Periods                                                           

                1.4 General Study Assumptions                                                

2. Research Methodology                                                                           

                2.1 Introduction                                                              

                2.2 Research Phases                                                      

                                2.2.1 Secondary Research                                            

                                2.2.2 Primary Research                                 

                                2.2.3 Econometric Modelling                                     

                                2.2.4 Expert Validation                                  

                2.3 Analysis Design                                                         

                2.4 Study Timeline                                                          

3. Overview                                                                      

                3.1 Executive Summary                                                

                3.2 Key Inferences                                                         

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                                                      

                4.1 Market Drivers                                                          

                4.2 Market Restraints                                                    

                4.3 Key Challenges                                                         

                4.4 Current Opportunities in the Market                                               

5. Market Segmentation                                                                              

                 5.1 By Hormone Type                                                   

                                5.1.1 Estrogen Replacement Therapy                                     

                                5.1.2 Growth Hormone Replacement Therapy                                   

                                5.1.3 Thyroid Replacement Therapy                                       

                                5.1.4 Others                                      

                5.2 By Route of Administration                                                 

                                5.2.1 Oral                                            

                                5.2.2 Parenteral                               

                                5.2.3 Transdermal                                           

                                5.2.4 Others                                      

6. Geographical Analysis                                                                              

                                6.1 Introduction                                              

                                6.2 United States                                            

                                6.3 Canada                                         

7. Pipeline Product Analysis                                                                       

                7.1 Overview                                                                    

                7.2 Pipeline Development Landscape                                                                    

                7.3 Molecular Targets in the Pipeline                                                                     

                7.4 Clinical Trials                                                             

                                7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target                                       

                                7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target                                                  

                                7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.                                               

8.Strategic Analysis                                                                        

                8.1 PESTLE analysis                                                         

                                8.1.1 Political                                     

                                8.1.2 Economic                                 

                                8.1.3 Social                                         

                                8.1.4 Technological                                         

                                8.1.5 Legal                                          

                                8.1.6 Environmental                                      

                8.2 Porter’s Five analysis                                                              

                                8.2.1 Bargaining Power of Suppliers                                        

                                8.2.2 Bargaining Power of Consumers                                    

                                8.2.3 Threat of New Entrants                                     

                                8.2.4 Threat of Substitute Products and Services                               

                                8.2.5 Competitive Rivalry within the Industry                                      

9.Market Leaders' Analysis                                                                          

                9.1 Abbott Laboratories                                               

                                9.1.1 Overview                                

                                9.1.2 Product Analysis                                   

                                9.1.3 Financial analysis                                  

                                9.1.4 Recent Developments                                       

                                9.1.5 SWOT analysis                                       

                                9.1.6 Analyst View                                          

                9.2 Novartis                                                       

                9.3 Pfizer                                                            

                9.4 Mylan Laboratories                                                 

                9.5 Amgen                                                         

                9.6 Merck & Co.                                               

                9.7 Bayer                                                            

                9.8 Eli Lily & Company                                                  

                9.9 Novo Nordisk                                                            

                9.10 Wyeth                                                        

                9.11 F. Hoffmann-La Roche                                                         

                9.12 Hisamitsu Pharmaceutical  Co. Inc.                                                 

10.Competitive Landscape                                                                          

                10.1 Market share analysis                                                          

                10.2 Merger and Acquisition Analysis                                                     

                10.3 Agreements, collaborations and Joint Ventures                                                       

                10.4 New Product Launches                                                       

11.Expert Opinions                                                                         

                11.1 Market Outlook                                                     

                11.2 Investment Opportunities                                                 


                a) List of Tables                                                

                b) List of Figures                                                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. North America Hormone Replacement Therapy Market By Region, From 2018-2023 (USD Billion)
  2. North America Hormone Replacement Therapy Market By Hormone Type, From 2018-2023 (USD Billion)
  3. North America Estrogen Replacement Therapy Market By Region, From 2018-2023 (USD Billion)
  4. North America Growth Hormone Replacement Therapy Market By Region, From 2018-2023 (USD Billion)
  5. North America Thyroid Replacement Therapy Market By Region, From 2018-2023 (USD Billion)
  6. North America Other Hormone Therapies Market By Region, From 2018-2023 (USD Billion)
  7. North America Hormone Replacement Therapy Market By Route of Administration, From 2018-2023 (USD Billion)
  8. United States Hormone Replacement Therapy Market By Hormone Type, From 2018-2023 (USD Billion)
  9. United States Hormone Replacement Therapy Market By Route of Administration, From 2018-2023 (USD Billion)
  10. Canada Hormone Replacement Therapy Market By Hormone Type, From 2018-2023 (USD Billion)
  11. Canada Hormone Replacement Therapy Market By Route of Administration, From 2018-2023 (USD Billion)


$ 1234 3335